In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Tarsus Pharmaceuticals (TARS – Research Report), with a price target of $60.00. The company’s shares closed ...

New York State Common Retirement Fund lowered its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Free Report) by 3.6% during the fourth quarter, Holdings Channel.com reports.